BSLN — Basilea Pharmaceutica AG, Allschwil Share News
0.000.00%
Last trade - 00:00- CH₣888.06m
- CH₣785.65m
- CH₣232.38m
Basilea seen up after raising 2026 guidance
Brief: Basilea Expects 2026 Operating Profit Of CHF 115 Mln
Brief: Basilea Reports Presentation Of New Data For Fosmanogepix, Isavuconazole And Ceftobiprole At IDWeek 2026
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Switzerland's Basilea H1 revenue rises on Cresemba demand; ups 2026 profit outlook
Brief: Basilea Pharmaceutica Raises FY 2026 Guidance
Swiss stocks - Factors to watch on August 18
Brief: Basilea Receives Additional USD 5.4 Million From Barda To Continue Development Of Novel Antibiotic Ceftibuten-Ledaborbactam
Brief: Basilea Receives $30 Million Funding For Advancing Phase 3 Development Of Novel Antifungal
Brief: Basilea Pharmaceutica Gets $13 Million From Barda For Ceftibuten-Ledaborbactam Development
Brief: Basilea Pharmaceutica Shareholders Approve All Board Proposals At 2026 AGM
Brief: Basilea Receives Additional USD 6 Million Funding From Carb-X
Brief: Basilea Receives USD 6 Mln From Barda For Antibiotic Ceftibuten-Ledaborbactam Development
Switzerland's Basilea revenue rises 11% on Cresemba demand
Brief: Basilea Pharmaceutica: 2026 Financial Guidance 10% Increase In Total Revenue Driving 20% Increase In Operating Profit
Brief: Basilea Pharmaceutica Announce Sales Performance Of Cresemba® Exceeded Threshold Triggering USD 5 Mln Milestone Payment
Brief: Basilea Pharmaceutica Announces A Partnership With INCATE
Brief: Basilea: Two New Preclinical Collaborations To Develop Novel Antibacterial And Antifungal Drugs
Brief: Basilea Pharmaceutica Announces Agreement With Prokaryotics